Analyst Ratings for Royalty Pharma (RPRX)
RPRX Rating Summary
RPRX Price Target Summary
- Highest: $56.00 (Goldman Sachs)
- Lowest: $42.44 (JPMorgan)
- Average: $49.68
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$49.68 (+18%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 76%
Rating Score: 7.5 / 10

Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
6/14/2022 | UBS | Ashwani Verma | New Coverage | Buy (N/A) |
47.00 (N/A) |
40.48 (42.09) |
3.98% | Details |
5/13/2022 | Scotiabank | Adam Buckham | New Coverage | Sector Outperform (N/A) |
53.00 (N/A) |
38.95 (42.09) |
8.06% | Details |
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |
||||||||
![]() |